Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

PURPOSE: CLL cells treated with dasatinib in vitro undergo apoptosis via inhibition of Lyn kinase. Thus, in this study we tested the activity of dasatinib in patients with relapsed CLL. EXPERIMENTAL DESIGN: Patients were eligible for this phase 2 trial if they had documented CLL/SLL and had failed a...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Amrein, Philip C., Attar, Eyal C., Takvorian, Tak, Hochberg, Ephraim P., Ballen, Karen K., Leahy, Kathleen M., Fisher, David C., LaCasce, Ann S., Jacobsen, Eric D., Armand, Philippe, Hasserjian, Robert P., Werner, Lillian, Neuberg, Donna, Brown, Jennifer R.
Formato: Artigo
Idioma:Inglês
Publicado: 2011
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3108904/
https://ncbi.nlm.nih.gov/pubmed/21402714
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-2879
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares